

# **Analysis of single-cell RNA-seq data (V)**

Hao Wu

Department of Biostatistics  
and Bioinformatics  
Rollins School of Public Health  
Emory University

Ziyi Li

Department of Biostatistics  
The University of Texas MD  
Anderson Cancer Center

ENAR 2021 short course  
March 2021

# Course outline


- 8-9:15: Intro and data preprocessing.
- 9:15-9:45: Lab: preprocessing and visualization.
- 10-11:15: Normalization, batch effect, imputation, DE, simulator.
- 11:15-12: Lab: Normalization, batch effect, imputation, DE, simulator
- 12-1: Lunch break
- 1-2: Clustering and pseudotime construction
- 2-2:30: Lab: Clustering and pseudotime construction
- 2:45–3:30: Supervised cell typing & related single cell data sources
- 3:30-4: Lab: supervised cell typing.
- **4:15-5: scRNA-seq in cancer**

# **Outline for this session**


- **Background**
  - Uniqueness of tumor tissue
  - Opportunities and challenges
- **Relevant computational methods**
  - Unified analysis across condition and multiple samples
  - Distinguishing neoplastic from nonneoplastic cells
  - Inferring communication with tumor microenvironment
  - Delineating tumoral and microenvironment evolution
  - Other tumor-specific topics
- **Future opportunities**

# Uniqueness of tumor tissue

a Normal




b Cancer




- Differentiation hierarchies is changed in cancer cells
- Different factors shape cellular phenotypes

Normal tissue: low phenotypic heterogeneity


Noise: low




Genotypes: homogeneous



Microenvironment: structured




Network architecture: robust



Tumour: high phenotypic heterogeneity


Noise: high




Genotypes: heterogeneous




Microenvironment: disorganized




Network architecture: noisy




# Uniqueness of tumor tissue



# Uniqueness of tumor tissue



# Single cell RNA-seq provides unbiased characterization of cell profiles in tumor environment



# Unified analysis across many patients and disease states

- Goal: identifying common cell types and states shared across patients and disease states from multiple scRNA-seq datasets.
- Batch effect is a big concern here.
- Batch correction tools: MultiCCA, MNN, combat, etc.
- Newly emerged tools: LIGER, Harmony, scVI, SAUCIE

# **Challenges in clustering: neoplastic cells**


- Neoplastic cells aggregate by patient due to the inter-patient heterogeneity for neoplastic versus non-neoplastic cells
- Neoplastic cells need to be considered separately from nonneoplastic cells
- Clustering per patient is also recommended to avoid over-correction
- Perform generic batch correction with caution

# Distinguishing neoplastic from nonneoplastic cells

- Neoplastic cells generally exhibit extensive alterations in a variety of biochemical pathways and oncogenic programs emblematic of cancer
- Certain cancers - distinct marker genes or combinations of marker genes
  - E.g. multiple myeloma cells are marked by CD38+/CD138+ antigen expression


# Distinguishing neoplastic from nonneoplastic cells (continue)

- Other cancers - marker gene or pathway are not enough
  - Neoplastic cells can also express genes and pathways typically associated with canonical nonneoplastic cells in ways that we might not expect.
  - CNV inference-based detection: InferCNV, CopyKAT
  - Point mutation-based detection: HoneyBADGER
  - some cancers are not well defined by either large-scale CNVs or somatic point mutations (chronic myeloid leukemia – BCR-ABLfusion)




# CopyKAT


**a**




**b**




**c**



**d**










**e**




# Inferring communication within the tumor microenvironment

- Infer putative communication of cell types: comparison of the expression levels of a receptor gene in one cell type and a corresponding ligand gene in another cell type
- Methods: CellPhoneDB (2018 Nature, 2020 Nature protocol), CellTalker (2020 Immunity), NicheNet (2020 Nature Methods), iTalk (bioRxiv, 2019)



# CellPhoneDB

## CellPhoneDB v1



1. Secreted (1943) and membrane (3127) proteins

- Uniprot
- Protein families
- Literature mining


3. Protein-protein interactions (1144)

- IUPHAR
- IMEX
- Literature mining

[www.CellPhoneDB.org](http://www.CellPhoneDB.org)

2. Protein complexes (126)

- Literature mining
- PDB



# Deconvolution of bulk RNA-seq using single cell RNA-seq data

- Infer proportions of different immune and stromal cell type
- Assumption: bulk sample is a mixture of multiple transcriptionally distinguishable cell types
- Methods: MuSiC (Wang et al. 2019, Nat Comm), CibersortX (Newman et al. 2019, Nature)
- Other: TIMER, Cibersort, MCP-counter, xCell
- Marker gene selection is important - cancer cells may aberrantly express genes associated with canonical immune or nonneoplastic cell types


# Delineating tumoral and microenvironmental evolution

- Pseudotime construction methods could be used for trajectory construction
- Special attention is needed for determining start and end point in trajectory construction
- RNA velocity analysis

# RNA velocity analysis

- Has been applied on some cancer studies, but not cancer specific. It is originally designed for capturing developmental trajectory.
- Balance between unspliced and spliced mRNAs is predictive of cellular state progression
- Increase in the transcription rate: a rapid increase in unspliced mRNA -> increase in spliced mRNA -> new steady state
- Drop in the rate of transcription: a rapid drop in unspliced mRNA -> reduction in spliced mRNA -> steady state
- Such spliced/unspliced states can be identified using protocols of SMART-seq2, inDrop, STRT/C1, and 10x genomics

# RNA velocity analysis





# CytoTRACE

## RESEARCH ARTICLE

### RESEARCH METHODS


## Single-cell transcriptional diversity is a hallmark of developmental potential

Gunsagar S. Gulati<sup>1\*</sup>, Shaheen S. Sikandar<sup>1\*</sup>, Daniel J. Wesche<sup>1</sup>, Anoop Manjunath<sup>1</sup>, Anjan Bharadwaj<sup>1</sup>, Mark J. Berger<sup>2†</sup>, Francisco Ilagan<sup>1</sup>, Angera H. Kuo<sup>1</sup>, Robert W. Hsieh<sup>1</sup>, Shang Cai<sup>3</sup>, Maider Zabala<sup>1‡</sup>, Ferenc A. Scheeren<sup>4</sup>, Neethan A. Lobo<sup>1‡</sup>, Dalong Qian<sup>1</sup>, Feiqiao B. Yu<sup>5</sup>, Frederick M. Dirbas<sup>6</sup>, Michael F. Clarke<sup>1,7</sup>, Aaron M. Newman<sup>1,8§</sup>




# CytoTRACE


1



2





3



Differentiation

Less More

## Integration of mouse bone marrow datasets



# Futures

- Single cell multi-omics: epigenetic heterogeneity and its interplay with transcriptional heterogeneity at the single-cell level
- Spatial transcriptomics
- International consortium: Human Cell Atlas, Human Developmental Cell Atlas, Pediatric Cell Atlas, HuBMAP, Human Tumor Atlas Network, LifeTime EU Flagship